Novartis v. Regeneron: Federal Circuit Affirms Syringe Patent Unpatentable
Novartis AG and its affiliates brought US9220631B2 — a syringe technology patent — to the Federal Circuit against Regeneron Pharmaceuticals. After 627 days of appellate proceedings, the court affirmed the underlying finding of unpatentability, extinguishing Novartis’s enforcement rights over this asset.
Federal Circuit closes syringe patent dispute, backing Regeneron
Novartis AG, Novartis Pharmaceuticals Corporation, and Novartis Technology, LLC (collectively, Novartis) appealed a patentability determination concerning US9220631B2, a patent directed to syringe technology used in drug delivery. The defendant-appellee, Regeneron Pharmaceuticals, Inc., had successfully challenged the patent’s validity at a lower tribunal. The case was filed on 5 January 2023 and litigated before the Court of Appeals for the Federal Circuit.
On 23 September 2024, the Federal Circuit issued its judgment affirming the lower tribunal’s finding of unpatentability. An affirmance at this level means the appellate court found no reversible legal or factual error in the decision below. For Novartis, the ruling forecloses any further enforcement of US9220631B2 unless a successful petition for en banc rehearing or Supreme Court certiorari is pursued — both of which face high procedural bars.
The 627-day duration suggests substantive briefing and possibly oral argument, consistent with a contested patentability question rather than a straightforward procedural dismissal. The underlying cancellation action and the ‘unpatentable’ basis of termination indicate the claims were found to lack novelty or non-obviousness. What specific prior art drove the determination, and whether any claim narrowing was attempted, remains beyond what the public docket alone reveals.
Filing to Unpatentable in 627 days
627 days — above the median Federal Circuit appeal duration of ~500 days
Federal Circuit affirms: what the unpatentability ruling means for both parties
Affirmance means the lower decision survives intact
When the Federal Circuit affirms, it signals that the appellate panel found no reversible error — whether legal, factual, or procedural — in the tribunal below. The original unpatentability finding is not merely upheld; it becomes final at this appellate level. Novartis cannot re-litigate the same patentability question in a lower court. The only remaining avenues are en banc rehearing or a petition for certiorari to the Supreme Court, both of which succeed rarely.
No reversible error foundUS9220631B2 is extinguished as an enforcement asset
For Novartis, the affirmance is commercially significant. US9220631B2 can no longer be asserted against Regeneron or, in practice, against any third party pursuing similar invalidity arguments — the Federal Circuit’s reasoning will carry persuasive weight in future proceedings. Any licensing revenue or exclusivity premised on this patent is effectively nullified. Novartis’s broader syringe and drug delivery portfolio may need reassessment to identify remaining enforceable assets.
Enforcement rights nullifiedRegeneron secures freedom to operate without this patent barrier
Regeneron’s successful defence at the Federal Circuit level eliminates US9220631B2 as a litigation risk for its syringe and drug delivery products. The affirmance also raises the bar for Novartis to reassert equivalent claims: any continuation or divisional patent from the same family will face heightened scrutiny given the recorded unpatentability finding. Regeneron’s legal team at Weil Gotshal achieved a clean appellate win with no remand obligations.
Clean appellate win for RegeneronSyringe patent landscape shifts in Regeneron’s favour
The Federal Circuit’s affirmance strengthens the precedent that the claimed syringe technology was unpatentable, which may embolden competitors and generic manufacturers to challenge related Novartis drug delivery patents. For the broader pharmaceutical packaging and device sector, the ruling suggests that syringe design claims require robust differentiation from prior art to survive post-grant review. Companies holding similar device patents should audit claim scope against the prior art record developed in this case.
Higher bar for syringe device claimsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Multinational pharmaceutical group — holder of syringe patent US9220631B2Search in Eureka ↗ |
| Co-Plaintiff | Novartis Pharmaceuticals Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Novartis Technology, LLC | Company | Search in Eureka ↗ |
| Defendant | Regeneron Pharmaceuticals, Inc. | Company | Regeneron Pharmaceuticals, Inc. — US biopharmaceutical company, successful patent challengerSearch in Eureka ↗ |
| Plaintiff counsel | Elizabeth Holland, Esq. | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Gerard J. Cedrone | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Joshua Weinger | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | William G. James II | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | William M. Jay | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Allen Overy Shearman Sterling US LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | Goodwin Procter LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Adam Banks | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Anish R. Desai | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Christopher Pepe | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Elizabeth Weiswasser | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Priyata Patel At | Attorney | Counsel for Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Weil Gotshal & Manages, LLP | Law Firm | Representing Regeneron Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED’ with an ‘unpatentable’ basis of termination — is dispositive and leaves no aspect of the lower ruling open for reconsideration at this appellate level. The court applied the substantial evidence standard to any factual findings on patentability and reviewed legal conclusions de novo; its affirmance indicates both standards were met in Regeneron’s favour. For Novartis, the patent is effectively cancelled with finality. For Regeneron, no remand conditions attach, and the judgment is immediately operative.
US9220631B2 — Syringe Drug Delivery Device Technology
US9220631B2 was filed under application number US13/750352 and granted to Novartis. The patent covers syringe technology in the context of pharmaceutical drug delivery — a domain that encompasses prefilled syringes, safety syringe mechanisms, and delivery devices integral to biologic and small-molecule administration. Device patents in this category typically protect structural and functional innovations in plunger, barrel, or needle-shield design, and are strategically valuable for controlling the administration pathway of proprietary drugs.
Syringe and drug delivery device patents occupy a critical enforcement layer in the pharmaceutical IP stack: they can extend commercial exclusivity beyond the active pharmaceutical ingredient patents themselves. For a company like Novartis — which relies on biologic delivery for major franchise products — a device patent like US9220631B2 can serve as both a competitive moat and a licensing asset. Its cancellation by the Federal Circuit removes one such layer and may invite scrutiny of adjacent device patents in the Novartis portfolio by competitors, including Regeneron.
Should you run an FTO analysis against US9220631B2?
While US9220631B2 has been found unpatentable and affirmed as such by the Federal Circuit, R&D and product teams developing syringe systems, prefilled drug delivery devices, or biologic administration platforms should not treat this ruling as a blanket clearance. Related patents in the same Novartis family — continuations, divisionals, or foreign equivalents — may still be in force. Any product team commercialising syringe or injectable device technology should confirm the full family landscape before assuming freedom to operate.
PatSnap Eureka’s FTO Search Agent can map the complete patent family around US9220631B2, identify surviving related claims across jurisdictions, and flag prosecution history estoppel created by this unpatentability finding. For device and drug delivery IP teams, Eureka’s claim-mapping tools help assess whether a proposed product design falls within the scope of still-active family members — a critical step before product launch or licensing negotiation in the pharmaceutical device space.
Run a freedom-to-operate analysis on US9220631B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit syringe and pharma device patent cases
Explore related Federal Circuit appeals involving pharmaceutical device and syringe patent unpatentability challenges, with comparable claim scope and invalidity arguments.
What this case signals for the pharma device IP landscape
A Federal Circuit affirmance on unpatentability carries real consequences beyond the two parties — here is what it means for IP teams in drug delivery.
Syringe and drug delivery device patents face elevated invalidity risk
This Federal Circuit affirmance signals that syringe technology claims are vulnerable to unpatentability challenges when prior art is well-developed. IP teams holding drug delivery device patents should audit claim scope now — particularly continuation patents from families with a recorded unpatentability finding — before a competitor files its own cancellation action.
Regeneron’s win removes a Novartis enforcement lever in biologics delivery
With US9220631B2 extinguished, Regeneron and similarly situated biologics manufacturers gain clearer freedom to operate around this syringe design. Competitors monitoring Novartis’s device patent portfolio should note that this ruling weakens one vector of enforcement and may signal increased vulnerability in related family members.
Novartis v Regeneron — key questions answered
The Federal Circuit affirmed the lower tribunal’s finding that US9220631B2 — a Novartis syringe patent — is unpatentable. The judgment, issued on 23 September 2024, leaves no aspect of the patentability determination open for reconsideration at this appellate level. Novartis’s enforcement rights over this patent are extinguished.
US9220631B2 is a Novartis patent filed under application number US13/750352. It covers syringe drug delivery device technology — the type of structural and functional innovations relevant to prefilled syringes and biologic administration platforms. The patent was central to the dispute between Novartis and Regeneron in both the lower proceeding and the Federal Circuit appeal.
An affirmance on unpatentability means the Federal Circuit found no reversible error in the cancellation of US9220631B2. For Novartis, this extinguishes the patent as an enforcement or licensing asset. It also creates a documented prior art record that could be used by competitors to challenge related patents in the same family. Novartis would need to pursue en banc rehearing or Supreme Court certiorari to reverse the outcome — both are procedurally demanding and rarely granted.
Regeneron’s successful challenge removes US9220631B2 as a patent risk for its syringe and drug delivery products. The Federal Circuit affirmance means no remand conditions attach and the judgment is immediately operative. Regeneron and similarly situated drug delivery companies gain clearer freedom to operate around the specific syringe claims that Novartis had sought to enforce.
The ruling specifically cancels US9220631B2 and does not automatically affect other patents. However, continuation, divisional, or foreign counterpart patents in the same Novartis family may remain in force. The unpatentability finding and the prior art record developed in this case could be leveraged in challenges to related family members. Companies in the drug delivery device space should conduct a full family landscape review to assess remaining risk.
PatSnap Eureka searches patents and litigation data to answer instantly.